BINOSTO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Binosto, and when can generic versions of Binosto launch?
Binosto is a drug marketed by Radius and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in BINOSTO is alendronate sodium. There is one drug master file entry for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the alendronate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Binosto
A generic version of BINOSTO was approved as alendronate sodium by AUROBINDO PHARMA on August 4th, 2008.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BINOSTO?
- What are the global sales for BINOSTO?
- What is Average Wholesale Price for BINOSTO?
Summary for BINOSTO
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 76 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,900 |
| Drug Prices: | Drug price information for BINOSTO |
| What excipients (inactive ingredients) are in BINOSTO? | BINOSTO excipients list |
| DailyMed Link: | BINOSTO at DailyMed |
Recent Clinical Trials for BINOSTO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, Davis | Phase 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Doris Duke Charitable Foundation | Phase 2 |
Pharmacology for BINOSTO
| Drug Class | Bisphosphonate |
US Patents and Regulatory Information for BINOSTO
BINOSTO is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radius | BINOSTO | alendronate sodium | TABLET, EFFERVESCENT;ORAL | 202344-001 | Mar 12, 2012 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BINOSTO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Radius | BINOSTO | alendronate sodium | TABLET, EFFERVESCENT;ORAL | 202344-001 | Mar 12, 2012 | ⤷ Start Trial | ⤷ Start Trial |
| Radius | BINOSTO | alendronate sodium | TABLET, EFFERVESCENT;ORAL | 202344-001 | Mar 12, 2012 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BINOSTO
See the table below for patents covering BINOSTO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 541575 | ⤷ Start Trial | |
| Australia | 2003219999 | EFFERVESCENT COMPOSITIONS COMPRISING BISPHOSPHONATES AND METHODS RELATED THERETO | ⤷ Start Trial |
| Australia | 2003284275 | EFFERVESCENT COMPOSITIONS COMPRISING BISPHOSPHONATES AND METHODS RELATED THERETO | ⤷ Start Trial |
| Canada | 2495886 | COMPOSITIONS EFFERVESCENTES CONTENANT DES BISPHOSPHONATES ETMETHODES CONNEXES (EFFERVESCENT COMPOSITIONS COMPRISING BISPHOSPHONATES AND METHODS RELATED THERETO) | ⤷ Start Trial |
| Denmark | 1490024 | ⤷ Start Trial | |
| European Patent Office | 1490024 | COMPOSITIONS EFFERVESCENTES CONTENANT DE L'ALENDRONATE (EFFERVESCENT COMPOSITIONS COMPRISING ALENDRONATE) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for BINOSTO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1175904 | 2007C/048 | Belgium | ⤷ Start Trial | PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch